Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
1(25%)
Results Posted
100%(1 trials)

Phase Distribution

Ph not_applicable
1
25%
Ph phase_3
2
50%

Phase Distribution

0

Early Stage

0

Mid Stage

2

Late Stage

Phase Distribution3 total trials
Phase 3Large-scale testing
2(66.7%)
N/ANon-phased studies
1(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

4

all time

Status Distribution
Active(1)
Completed(1)
Other(2)

Detailed Status

unknown2
Recruiting1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
1
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 32 (66.7%)
N/A1 (33.3%)

Trials by Status

recruiting125%
unknown250%
completed125%

Recent Activity

1 active trials
Showing 4 of 4
recruitingphase_3

Intra-arterial Thrombolysis For Acute Ischemic Stroke With Medium Vessel Occlusion

NCT07668323
unknownnot_applicable

Strategy Therapy on Cancer Therapy-Related Cardiac Dysfunction

NCT05892146
unknown

Clinical Characteristics, Natural Outcome and Treatment Optimization of Refractory

NCT05376124
completedphase_3

Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031)

NCT01594749

Clinical Trials (4)

Showing 4 of 4 trials
NCT07668323Phase 3

Intra-arterial Thrombolysis For Acute Ischemic Stroke With Medium Vessel Occlusion

Recruiting
NCT05892146Not Applicable

Strategy Therapy on Cancer Therapy-Related Cardiac Dysfunction

Unknown
NCT05376124

Clinical Characteristics, Natural Outcome and Treatment Optimization of Refractory

Unknown
NCT01594749Phase 3

Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031)

Completed

All 4 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
4